In keeping with previously published data14–16, we saw a decrease in naive CD8+ T cells, with corresponding increase in the CD8+ terminally differentiated effector memory (TEMRA) population when comparing close-to-treatment CLL samples to HDs (Supplementary Fig. 5). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.